Please assess the completion status of the following clinical trial:

Trial Title: An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant has completed the 6-Month Treatment Period of their respective Pivotal Study (either Study M12-815 or Study M12-817).~* Participant did not meet removal criteria in bone mineral density (BMD) decrease in the spine, total hip and femoral neck at Month 6 of the Treatment Period of their respective Pivotal Study~* Participant has negative urine and/or serum pregnancy test(s) results were consistently negative during the Treatment Period of their respective Pivotal Study and prior to first dose in this study.~* Participant's endometrial biopsy from the Month 6 Visit of their respective Pivotal Study shows no clinically significant endometrial pathology.~Exclusion Criteria:~* Participant met criteria for removal from therapy in her respective Pivotal Study.~* Participant is planning a pregnancy within the next 18 months.~* Participant has current suicidal markers as noted at the Month 6 visit of her respective pivotal study.~* Participant has any new medical conditions that may be unsuitable for participation.~* Participant is using any systemic corticosteroids for over 14 days or is likely to require treatment with systemic corticosteroids during the course of the study. Over-the-counter and prescription topical, inhaled, intranasal or injectable (for occasional use) corticosteroids are allowed.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 51 Years
- Healthy Volunteers: f

Study Arms:
- Elagolix plus Estradiol/Norethindrone Acetate (E2/NETA) (Type: EXPERIMENTAL): Elagolix 300 mg twice daily (BID) and E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) once daily (QD)
- Elagolix (Type: EXPERIMENTAL): Elagolix 300 mg BID and placebo for E2/NETA (estradiol 1.0 mg/norethindrone acetate 0.5 mg) QD

Based on this trial design, predict the completion outcome and termination type (if applicable).